AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin disease FDA granted HUMIRA orphan drug designation for moderate to severe HS (Hurley Stage II and Hurley Stage III disease) in May NORTH CHICAGO, Ill., Sept. 10, 2015 -- (Healthcar... Biopharmaceuticals, Dermatology, FDAAbbVie, hidradenitis suppurativa, HUMIRA, adalimumab)
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news